biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Disappointing response by the market

<< Previous

Bullboard Posts

Next >>

Comment by chrispion Jul 08, 2021 12:53pm

147 Views

Post# 33515110

RE:Disappointing response by the market

Sometimes it takes more than 1.5 hours for people to digest the news ;) ... especially during the summer holiday season. But more importantly than the market realizing, or not, the importance and significance of this successful study, is that our current and future partners are now aware of it. That will help licensing negotiations with current and future partners!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing